MCL Literature Feed

This pediatric pathology study is not relevant to mantle cell lymphoma; it repurposes the BCL-1/Cyclin D1 IHC stain to diagnose Hirschsprung disease, a non-malignant gastrointestinal disorder.

This study evaluates the outcomes of Rituximab-Bendamustine (RB) versus the CHASER regimen as induction therapy for transplant-eligible mantle cell lymphoma, informing pre-transplant treatment selection.

Preclinical Galectin-9 induces cell death in MCL cell lines by disrupting autophagy, a novel, apoptosis-independent mechanism to potentially overcome chemoresistance.

This case report details an exceptionally rare extranodal MCL presentation in the lacrimal drainage system, emphasizing its inclusion in the differential diagnosis for masses in this location.

This case report demonstrates CNS relapse in an MCL patient with a low Ki-67 (10%), underscoring the need for CSF analysis in symptomatic patients regardless of proliferation index.

This review outlines the potential of AI-based PET/CT radiomics to improve lymphoma diagnosis and prognosis, but its specific clinical application in MCL remains undefined pending further research.

This case report describes a hyperacute, aggressive presentation of small cell, non-nodal MCL, highlighting the clinical heterogeneity and challenging prognostic assumptions for this typically indolent subtype.

This SEER database analysis confirms older age and advanced stage interact to worsen survival, while also identifying widowed marital status as an independent predictor of higher mortality in MCL.

This case report describes an MCL diagnosis in a patient with mucous membrane pemphigoid, where frontline acalabrutinib and rituximab resolved both conditions, suggesting a paraneoplastic link.

Italian experts established consensus diagnostic and therapeutic pathways for MCL, standardizing care while highlighting ongoing debates on MRD utility, immunotherapy sequencing, and CAR-T versus bispecifics.

This case report demonstrates that MCL can rarely cause membranous nephropathy, a severe renal complication that can be fully resolved by successfully treating the underlying lymphoma with chemotherapy.

This preclinical rat study shows the antifungal posaconazole increases zanubrutinib plasma exposure, highlighting a significant drug-drug interaction that may necessitate dose adjustments in MCL patients to avoid toxicity.

A novel MIPI/CD3 prognostic model using Quantitative Dot Blot to measure T-cell infiltration improves risk stratification, showing high CD3+ T-cells correlate with better outcomes in MCL.

This retrospective study suggests a 1-day bendamustine regimen for MCL offers comparable progression-free survival to the standard 2-day schedule but with significantly less neutropenia and adverse events.

A case of ganciclovir-resistant CMV encephalitis in a pirtobrutinib-treated MCL patient highlights a rare but severe infectious complication, urging vigilance for CNS symptoms with this non-covalent BTKi.

This case report of a non-MCL conjunctival lymphoma notes that MCL is a rare cause, highlighting an uncommon site of extranodal disease for MCL patients.

A case report of an elderly MCL patient with sequential relapses in rare extranodal sites (ocular adnexa, soft tissue, heart) highlights the need for vigilance for unusual disease presentations.

This case report details the rare co-occurrence of MCL and a tubular adenoma within a single colonic polyp, emphasizing the need for pathologists to carefully evaluate lymphoid aggregates in polyps.

This case report highlights how inadequate bone marrow sampling can lead to diagnostic errors, underscoring the critical need for proper technique to ensure accurate MCL staging and diagnosis.

Ibrutinib oral suspension has comparable bioavailability to tablets/capsules and is compatible with enteral tubes, providing a crucial administration option for MCL patients with dysphagia or requiring tube feeding.

This 20-year Taiwanese retrospective study confirms that frontline rituximab, intensive chemotherapy, and autologous transplant are associated with improved survival, validating these established strategies in a real-world Asian cohort.

Spontaneous splenic rupture is a rare but life-threatening initial presentation of MCL, requiring emergency splenectomy which can lead to the diagnosis, as highlighted by this case report.

This CLL study reveals venetoclax rapidly activates a BAFF-driven survival axis in residual tumor cells, a key resistance mechanism potentially targetable in MCL to deepen BCL2i responses.

Epigenetic profiling reveals a unique DNA methylation signature for B-cell prolymphocytic leukemia, providing a novel biomarker to differentiate it from its mimics, including mantle cell lymphoma.

The novel, chemotherapy-free triplet of alisertib, ibrutinib, and rituximab demonstrates clinical activity in MCL, providing a new therapeutic strategy for likely relapsed/refractory patients.

This large retrospective study of 476 MCL patients aged ≥80 provides crucial real-world outcome data, informing treatment selection and expectations in the very elderly population.

This case report illustrates the diagnostic challenge of distinguishing mantle cell lymphoma from chronic lymphocytic leukemia, emphasizing the critical role of specific pathological and cytogenetic markers for accurate diagnosis.

This preclinical study explains bortezomib-induced pulmonary toxicity, showing it increases endothelial RhoA/RhoC proteins, which synergize with inflammation to cause vascular hyperpermeability and capillary leak syndrome.

In newly diagnosed MCL, PET/CT-based bone marrow assessment has greater prognostic value than biopsy and is incorporated into a new MCL-PET-I index for improved risk stratification.

This case report describes a rare MCL CNS relapse presenting as Horner syndrome and oculomotor nerve palsy, highlighting the need for CSF analysis in patients with atypical neurological symptoms, even with normal imaging.